Page 75 - Read Online

Page 164 Shad. J Transl Genet Genom 2023;7:141-65 https://dx.doi.org/10.20517/jtgg.2023.11

review and meta-analysis. Eur Neuropsychopharmacol 2016;26:163-85. DOI PubMed
145. Schäfer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the
dopamine D receptor gene. Am J Psychiatry 2001;158:802-4. DOI
2
146. Suzuki A, Kondo T, Otani K, et al. Association of the TaqI A polymorphism of the dopamine D receptor gene with predisposition to
2
neuroleptic malignant syndrome. Am J Psychiatry 2001;158:1714-6. DOI
147. Vijayan NN, Bhaskaran S, Koshy LV, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic
response in a South Indian population. Behav Brain Funct 2007;3:34. DOI PubMed PMC
148. Dahmen N, Müller MJ, Germeyer S, et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects
in schizophrenic patients. Schizophr Res 2001;49:223-5. DOI
149. Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological predictors of clozapine response: a systematic
review. Front Psychiatry 2018;9:327. DOI PubMed PMC
150. Numata S, Umehara H, Ohmori T, Hashimoto R. Clozapine pharmacogenetic studies in schizophrenia: efficacy and agranulocytosis.
Front Pharmacol 2018;9:1049. DOI PubMed PMC
151. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E. Interaction between NOTCH and catechol-O-
4
methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004;14:303-7.
DOI PubMed
152. Huang E, Zai CC, Lisoway A, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic
treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. Int J Neuropsychopharmacol 2016;19:pyv132.
DOI PubMed PMC
153. Molero P, Ortuño F, Zalacain M, Patiño-García A. Clinical involvement of catechol-O-methyltransferase polymorphisms in
schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.
Pharmacogenomics J 2007;7:418-26. PubMed
154. Weickert TW, Goldberg TE, Mishara A, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory
response to antipsychotic medications. Biol Psychiatry 2004;56:677-82. DOI
155. Szekeres G, Kéri S, Juhász A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in
cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B
Neuropsychiatr Genet 2004;124B:1-5. DOI
156. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55 Suppl B:47-52. PubMed
157. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.
Schizophr Res 1998;32:93-9. DOI
158. Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and
drug response variability. J Psychiatry Neurosci 1999;24:141-6. PubMed PMC
159. Arranz MJ, Li T, Munro J, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene
and clozapine response. Pharmacogenetics 1998;8:481-4. DOI
160. Hamdani N, Bonnière M, Adès J, Hamon M, Boni C, Gorwood P. Negative symptoms of schizophrenia could explain discrepant data
on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 2005;377:69-74. DOI PubMed
161. Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A
receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008;8:40. DOI PubMed PMC
162. Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014;13:1163-91.
PubMed PMC
163. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of the 5-HT5A gene in depression,
psychosis and antipsychotic response. Neuroreport 2000;11:2017-20. DOI PubMed
164. Gutiérrez B, Arranz MJ, Huezo-Diaz P, et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine
response. Schizophr Res 2002;58:93-7. DOI PubMed
165. Wang L, Fang C, Zhang A, et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom
response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008;22:904-9. DOI
166. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and
depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006;163:1826-9. DOI
PubMed
167. Mössner R, Schuhmacher A, Kühn KU, et al. Functional serotonin 1A receptor variant influences treatment response to atypical
antipsychotics in schizophrenia. Pharmacogenet Genomics 2009;19:91-4. DOI
168. Masellis M, Basile VS, Meltzer HY, et al. Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6)
polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001;47:49-58. DOI
169. Schumacher J, Schulze TG, Wienker TF, Rietschel M, Nöthen MM. Pharmacogenetics of the clozapine response. Lancet
2000;356:506-7. PubMed
170. Tsai SJ, Hong CJ, Yu YW, et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia,
psychopathology and clozapine response. Schizophr Res 2000;44:177-81. DOI
171. Arranz MJ, Bolonna AA, Munro J, Curtis CJ, Collier DA, Kerwin RW. The serotonin transporter and clozapine response. Mol
Psychiatry 2000;5:124-5. DOI PubMed